NCT04961684CompletedNot Applicable
Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Oystershell NV
- Enrollment
- 76
- Locations
- 1
- Primary Endpoint
- Percentage of healthy surface (performance)
Study Overview
Brief Summary
The efficacy and safety of Solver Pen (prototype number X92001704) is evaluated in this randomized, open label, controlled, investigator-blinded, comparative clinical trial in 76 patients. Subjects are treated with either the test medical device (Solver Pen) or the comparator (Loceryl, 5% amorolfine), respectively, for a period of 90 days. The primary objective of the investigation is the increase of percentage of healthy surface on the great toenail at study end versus baseline, as evaluated by a blinded investigator. Patients are followed up for a period of 90 days, with visits at D0 (baseline), D30, D60 and D90, respectively.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient having given her/his informed, written consent.
- •Patient cooperative and aware of the modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.
- •Patient being psychologically able to understand information and to give their/his/her consent.
- •Age: more than 18 years.
- •Subject with superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement <2/3 of the tablet).
- •Patient with positive KOH staining.
- •Patient having stopped any systemic antifungal treatment since at least 6 months before inclusion and/or any topical antifungal treatment since at least 3 months before inclusion.
- •Women of childbearing potential should use an accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after study end.
Exclusion Criteria
- •Pregnant or nursing woman or planning a pregnancy during the investigation;
- •Patient considered by the Investigator likely to be non-compliant with the protocol.
- •Patient enrolled in another clinical trial during the test period.
- •Subject having a known allergy to one of the constituents of the tested products.
- •Patient with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk;
- •Patient suffering from serious or progressive diseases (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology...
- •Subject with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis...).
Arms & Interventions
Loceryl 5%
Active Comparator
Intervention: Loceryl 5% (Drug)
Solver Pen
Experimental
Intervention: Solver Pen (Device)
Outcomes
Primary Outcomes
Percentage of healthy surface (performance)
Time Frame: 90 days
Variation of the percentage of healthy surface after 90 days of treatment with the test medical device or reference versus baseline value. Evaluation is done in blind by digital analysis of photographs of the great, infected toenail.
Secondary Outcomes
- Microbiological efficacy: fungal culture (performance)(90 days)
- Clinical efficacy: nail discoloration (performance)(30, 60 and 90 days)
- Percentage of healthy surface (performance)(30 and 60 days)
- Microbiological efficacy: KOH staining (performance)(90 days)
- Clinical efficacy: onychomycosis evolution (performance)(30, 60 and 90 days)
- Clinical efficacy: nail distrophy (performance)(30, 60 and 90 days)
- Subjective evaluation questionnaire for the patient (performance)(14, 30, 60 and 90 days of treatment)
- Assessment of local tolerance by the investigator (safety and tolerability)(30, 60 and 90 days)
- Clinical efficacy: onycholysis (performance)(30, 60 and 90 days)
- Incidence of Adverse events (safety and tolerability)(30, 60 and 90 days)
- Clinical efficacy: nail thickening (performance)(30, 60 and 90 days)
- Impact on quality of life (performance)(60 and 90 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
To study the clinical effect and molecular mechanisms of herbal formulation in combating Covid-19CTRI/2022/09/045632All India Institute of Ayurveda
Completed
Phase 2
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based ChemotherapyNausea and VomitingChemotherapy-InducedNCT00169572GlaxoSmithKline492
Completed
Not Applicable
Clinical and Usability Study to Determine Safety and Efficacy of the Clear Device for Acne TreatmentMonitor Acne Lessions Count Reduction as Result of Usinfg the DeviceNCT01678482Home Skinovations Ltd.50
Completed
Phase 3
DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-upNasolabial Fold WrinklesNCT00444353Bausch Health Americas, Inc.240
Completed
Phase 3
DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold WrinklesNasolabial Fold WrinklesNCT00444210Bausch Health Americas, Inc.240